The cannabis industry has made a significant shift in its lobbying efforts in Washington. Major players like Curaleaf, Columbia Care, and Pax Labs have reduced or eliminated their lobbying teams, leading to a decline in spending on advocacy by more than 50% since 2019. This reduction in lobbying is a clear indication of the challenges that the cannabis industry is currently facing.
One of the primary reasons for this pullback is the financial hardships that cannabis companies are experiencing. Despite the growing acceptance of marijuana, the industry is still hindered by federal regulations. Companies are ineligible for tax breaks, struggle to access business loans, and even face difficulties in opening bank accounts. These limitations have resulted in financial losses and have forced companies to cut back on their government relations spending.
While the industry’s scaling back is seen by some as premature, it poses a potential threat to the progress made by the cannabis industry in Washington. Recent years have seen the introduction of several bills by both Republicans and Democrats that aim to legalize or decriminalize marijuana at the federal level. However, without the support of effective lobbying efforts, advocates fear that these bills may not gain enough traction to become law.
Despite the overall decline, a new coalition known as the U.S. Cannabis Council has emerged to take up some of the lobbying efforts. This group, which formed in 2021, aims to unify the cannabis industry’s message on Capitol Hill and has invested significant resources in its lobbying activities. Additionally, other lobbying groups like the American Trade Association For Cannabis and Hemp have modestly increased their lobbying efforts in recent months.
Looking at the broader landscape, the cannabis industry’s lobbying strategy seems to be evolving. While there is less overall spending, companies are becoming more focused and pragmatic in their approach. This shift may lead to more targeted efforts and potentially more success in influencing legislation.
However, it’s worth noting that some lobbying groups, particularly those representing small cannabis companies, have struggled in recent months. The National Cannabis Industry Association, for example, has seen a significant decline in membership and has been forced to make substantial cuts to its lobbying efforts. The organization has experienced a decrease in revenue, gone through layoffs, and now employs only six full-time staff members, with just one registered lobbyist.
In conclusion, the cannabis industry’s scaling back on lobbying in Washington reflects the challenging environment it faces due to federal regulations. While some new coalitions and lobbying groups have emerged, the overall decrease in lobbying spending raises concerns about the industry’s ability to make progress on federal legalization or decriminalization. As the industry continues to navigate these challenges, it remains to be seen how effective lobbying efforts will be in shaping future cannabis legislation in Washington.
0 Comments